IBInes Bojanić

Ines Bojanić

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ines Bojanić has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real‐World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System

    by Aaron Haubner, Sebastian Mendoza, Hans Vrielink, Volker Witt, Dries Deeren, Ines Bojanic, Zdenka Gasova, Astrid Aandahl, Tanya Nadia Glatt, Ana Maria Vasilache, et al.

    In this study we analyzed 12 years of adverse events, (AE) data from the World Apheresis Association, (WAA) Registry specific to the Spectra Optia Apheresis System. We queried WAA Registry data, (2012–2023) on apheresis procedures performed exclusively on the Spectra Optia Apheresis System. We categorized AEs by severity, (mild, moderate, and severe), and ordered them by year. We then analyzed and presented AEs associated with the following variables: diagnosis, procedure type, vascular access, and replacement fluid type, and causes of procedural interruption. We identified 51 567 apheresis procedures specific to the Spectra Optia Apheresis System within the data set. AE rates from 2012 to 2023 for mild, moderate, and severe were 1.43%, 2.81%, and 0.21%, respectively. Procedures associated with the lowest AE rates include red blood cell exchange and therapeutic plasma exchange. The most common mild and moderate AEs include tingling and hypotension and AEs related to vascular access. The highest rates of mild and moderate AEs were associated with cellular collections. The highest rate of severe AEs was associated with the use of 3.5% albumin as replacement fluid. Other variables impacting patient safety are identified. AE rates could not be compared to the median length of procedure since this time variable is not currently collected in the Registry. This is the first device‐specific analysis of the WAA Registry data, bringing prior safety reporting into even sharper focus. Device‐specific safety analysis like this will help practitioners better understand potential safety concerns associated with a commonly used apheresis device, including various separation modalities and accessories, thus supporting improved procedure management.


  • The effect of prophylactic extracorporeal photopheresis on cardiac allograft vasculopathy during the first post-transplant year in de novo heart transplant recipients: ECP-OCT2019 study design

    by Mia Dubravčić Došen, Hrvoje Jurin, Marijan Pašalić, Branka Golubić Ćepulić, Ines Bojanić, Sanja Mazić, Dora Fabijanović, Nina Jakuš, Ivo Planinc, Jure Samardžić, et al.

  • Open Access

    The impact of cryoprotectant exposure time on post-thaw viability of autologous and allogeneic hematopoietic stem cells and leukocyte subpopulations

    by Vladimira Rimac, Ines Bojanić, Sanja Dabelić, Branka Golubić Ćepulić

    Although the use of cryoprotectant dimethyl sulfoxide (DMSO) is the gold standard in cryopreservation of hematopoietic stem cells, it is well known that it has a negative effect on cell viability. The aim of this prospective study was to examine how the length of post-thaw exposure to DMSO affects the cell viability and stability of peripheral blood stem cell (PBSC) samples. Additionally, the effects of donor type and pre-cryopreservation storage time on post-thaw viability during the stability study were evaluated. In 30 autologous and 30 allogeneic PBSC samples viable CD34+, CD14+, CD19+, CD16+/56+, and CD3+ cells were determined immediately after thawing, and one-and three-hours post-thaw. Analysis of the absolute count of viable cells in thawed samples showed a significant difference between all measurement points for CD34+ ( p < 0.001), CD14+ ( p < 0.001), and CD19+ cells ( p < 0.001). No significant differences were observed for post-thaw stability of allogeneic samples analysed between products stored before cryopreservation ≥ 24 hours (N = 20), and those stored < 24 hours (N = 10), except for viable CD3+/CD4+ cells after three hours post-thaw ( p = 0.028). In conclusion, DMSO had different effects on leukocyte subpopulations in cryopre-served PBSC samples. The type of donors and the length of storage before cryopreservation did not affect the post-thaw stability of cryopreserved PBSC samples.


  • Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience

    by Ines Bojanić, Greta Novosel, Marijana Lukač Baričević, Petar Škrnjug, Elena Horvat, Sanja Mazić, Josip Batinić, Sandra Bašić Kinda, Branka Golubić Ćepulić

    Introduction: Peripheral blood stem cell (PBSC) harvesting requires reliable and safe vascular access. In our institution, a change of practice was implemented and the central venous catheter (CVC) placement for all autologous PBSC collections was abandoned in favor of a careful evaluation of peripheral venous access (PVA) for each individual patient. The aim of this prospective study was to evaluate the rate of patients with adequate peripheral veins for autologous PBSC collection and compare patient characteristics, collection efficacy, and complication rate between patients with PVA and CVC.Method: Peripheral veins were assessed by the apheresis nurse team in all patients referred between January 2020 and July 2021 to autologous PBSC collection. Only in case of difficult venous access, CVC was inserted. Large volume leukapheresis (LVL) procedures, which processed ≥3 total blood volumes, were performed.Results: In 65 (57%) patients PVA was used, while 49 (43%) patients required placement of short‐term CVC. Peripheral venous access was successfully used significantly more often in males (69.8%) (P = 0.010), and patients with multiple myeloma (71.0%) than in patients with non‐Hodgkin's lymphoma (35.9%) and Hodgkin's lymphoma patients (33.3%) (P < 0.001). There was a significant difference in the type of prior administered chemotherapy; in the patients who received cytostatics free chemotherapy, PVA was used more often (75.0%) (P = 0.007). In terms of the efficacy and safety of LVLs, there were no differences between procedures performed using PVA and CVCs.Conclusion: Peripheral venous access is feasible for autologous PBSC collection in more than a half of patients, in particular in those with multiple myeloma. Changes in the treatment of multiple myeloma, using new proteasome inhibitors‐based and immunomodulatory agents that do not adversely affect peripheral veins, have enabled the use of PVA even at the high blood flow rates required by LVL. Peripheral venous access is not associated with safety issues or with a lesser collection efficiency, and it is cost‐effective as well. Each patient referred to autologous PBSC collection needs to be evaluated individually by the experienced apheresis team for the most appropriate venous access.


  • Open Access

    The effect of anticoagulation therapy on perioperative bleeding risk in patients undergoing heart transplantation

    by Petra Mjehović, Mia Dubravčić Došen, Marijan Pašalić, Maja Čikeš, Dora Fabijanović, Nina Jakuš, Hrvoje Jurin, Daniel Lovrić, Ivo Planinc, Jure Samardžić, et al.

  • Desensitization procedures in heart transplant recipients: a case series

    by Mia Dubravčić Došen, Petra Mjehović, Dubravka Šipuš, Maja Čikeš, Dora Fabijanović, Nina Jakuš, Hrvoje Jurin, Daniel Lovrić, Marijan Pašalić, Ivo Planinc, et al.

  • Open Access

    Impact of COVID-19 pandemic on collection of allogeneic hematopoietic stem cells

    by Klinički Zavod, Ivona Horvat, Ines Bojanić, Sanja Mazić, Nadira Duraković, Radovan Vrḫovac, Branka Golubić Ćepulić

  • Changes in the incidence of transfusion reactions in hematological patients over the past 30 years

    by Ines Bojanić, Marija Lukić, Fini Plenković, Mirela Raos, Marta Medenjak, Branka Golubic Ćepulić

    Background: Patients with hematological diseases are polytransfused and often immunocompromised, therefore susceptible to transfusion reactions (TR). This study aims to document the incidence of TRs in adult hematological patients and assess the effect of changes in the production of blood components and transfusion practice on their occurrence.Study design and methods: Retrospective observational analysis of TRs reported from 1993 to 2019 was performed. For the analysis of the effect of changes on the incidence of TRs, the evaluated time was divided into two periods: the 1st period before the introduction of changes in production, when leukoreduced blood components were used only selectively, and the 2nd period, when semi‐automated method of production and universal leukoreduction was introduced.Results: The decrease in the incidence of TRs was observed for both red blood cell (RBC) and platelet concentrate (PC) transfusions in the 2nd period. Since platelet additive solution has been used, a further decrease in the incidence was reported. The decrease in incidence was also observed for delayed hemolytic/serological transfusion reactions and for transfusion‐transmitted bacterial infections. Four cases of incorrect blood transfusions were uniquely related to the hematological patients, caused by antigen loss and transfusion ordering after ABO‐incompatible hematopoietic stem cell transplantation.Discussion: Our results provided evidence that the introduction of tools offered by modern transfusion medicine: universal leukodepletion, plasma replacement with additive solutions, sensitive laboratory techniques, prophylactic antigen matching policy, informatization, and automatization, decreased the incidence of TRs and improved transfusion safety.